secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2026-07-02T20:10:05+00:00
Accession:  0001378325-26-000026
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CapsoVision appoints Dr. David Shields to board; Dr. Imperial resigns but remains consultant
--------------------------------------------------------------------------------

- Dr. David Shields, a gastroenterologist with 40+ years experience and capsule endoscopy pioneer, appointed Class I director and Compensation Committee member effective July 1, 2026.
- Dr. Joanne Imperial resigned as director effective July 1, 2026; no disagreement with management or board.
- Dr. Imperial will continue as independent consultant at $600/hour, up to 5 hours/week, and received option for 10,000 shares vesting over 4 years.
- Dr. Shields will provide clinical consulting at $600/hour, up to 3 hours/week, under a separate consulting agreement.
- Dr. Imperial to advise on pancreatic cancer program and planned 2027 esophageal varices study using next-gen capsule platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000026/0001378325-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000026/cv-20260701.htm
  HTML page:      https://secwatch.observer/filing/0001378325-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer